药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Catumaxomab
The risk or severity of adverse effects can be increased when Catumaxomab is combined with Polatuzumab vedotin.
Difenoxin
Teplizumab
The risk or severity of adverse effects can be increased when Teplizumab is combined with Polatuzumab vedotin.
Difenoxin
Reslizumab
The risk or severity of adverse effects can be increased when Reslizumab is combined with Polatuzumab vedotin.
Difenoxin
Lexatumumab
The risk or severity of adverse effects can be increased when Lexatumumab is combined with Polatuzumab vedotin.
Difenoxin
Lerdelimumab
The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Polatuzumab vedotin.
Difenoxin
Bivatuzumab
The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Polatuzumab vedotin.
Difenoxin
Sibrotuzumab
The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Polatuzumab vedotin.
Difenoxin
Apolizumab
The risk or severity of adverse effects can be increased when Apolizumab is combined with Polatuzumab vedotin.
Difenoxin
Siplizumab
The risk or severity of adverse effects can be increased when Siplizumab is combined with Polatuzumab vedotin.
Difenoxin
Pertuzumab
The risk or severity of adverse effects can be increased when Pertuzumab is combined with Polatuzumab vedotin.
Difenoxin
Lucatumumab
The risk or severity of adverse effects can be increased when Lucatumumab is combined with Polatuzumab vedotin.
Difenoxin
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Polatuzumab vedotin.
Difenoxin
XmAb 2513
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Polatuzumab vedotin.
Difenoxin
Carotuximab
The risk or severity of adverse effects can be increased when Carotuximab is combined with Polatuzumab vedotin.
Difenoxin
Elotuzumab
The risk or severity of adverse effects can be increased when Elotuzumab is combined with Polatuzumab vedotin.
Difenoxin
Motavizumab
The risk or severity of adverse effects can be increased when Motavizumab is combined with Polatuzumab vedotin.
Difenoxin
Sonepcizumab
The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Polatuzumab vedotin.
Difenoxin
BIIB015
The risk or severity of adverse effects can be increased when BIIB015 is combined with Polatuzumab vedotin.
Difenoxin
Clenoliximab
The risk or severity of adverse effects can be increased when Clenoliximab is combined with Polatuzumab vedotin.
Difenoxin
Nimotuzumab
The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Polatuzumab vedotin.